Cite
HARVARD Citation
Avogaro, A. et al. (2018). When metformin is not enough: Pros and cons of SGLT2 and DPP‐4 inhibitors as a second line therapy. Diabetes/metabolism research and reviews. 34 (4), p. n/a. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Avogaro, A. et al. (2018). When metformin is not enough: Pros and cons of SGLT2 and DPP‐4 inhibitors as a second line therapy. Diabetes/metabolism research and reviews. 34 (4), p. n/a. [Online].